There were no new safety signals with cemiplimab plus chemotherapy in the phase 2 EPIC-A trial, Challapalli stated.
Amarnath Challapalli, MBBS, MD, MRCP-UK, FRCR, PhD
Advertisement
Articles by Amarnath Challapalli, MBBS, MD, MRCP-UK, FRCR, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Zipalertinib Yields Early Activity in EGFR+ NSCLC CNS Metastasis Population
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
5
